EUVIMEDEUVIMED entdecken
Open Access

DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX

Megan Coylewright, David R Holmes, Samir R Kapadia, Jonathan C Hsu, Douglas N Gibson, James V Freeman, Robert W Yeh, Jonathan P Piccini, Matthew J Price, Dominic J Allocco, Devi G Nair

JACC: Cardiovascular Interventions · 2023-11 · 16 (22) · 2708-2718

DOI: 10.1016/j.jcin.2023.08.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2023-11. Verfasst von Megan Coylewright und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Tennessee Health Science Center College of Medicine-Chattanooga and Erlanger Health System, Chattanooga, Tennessee, USA. Electronic add…. Hauptthemen laut MEDLINE: Atrial Appendage, Stroke, Atrial Fibrillation, Thrombosis. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Left atrial appendage occlusion (LAAO) is an approved alternative for stroke prevention in atrial fibrillation for patients with an "appropriate rationale" to avoid long-term oral anticoagulation (OAC). Many patients undergoing LAAO are at high risk of bleeding. OBJECTIVES: This study sought to investigate whether dual antiplatelet therapy (DAPT) is a safe alternative to OAC (direct oral anticoagulation [DOAC] or warfarin) with aspirin after LAAO. METHODS: Using National Cardiovascular Data Registry LAAO registry data, patients undergoing Watchman FLX (Boston Scientific) implantation (August 5, 2020-September 30, 2021) were included in 1:1 propensity-matched analyses comparing discharge medication regimens (DAPT, DOAC/aspirin, or warfarin/aspirin). A composite endpoint (death, stroke, major bleeding, and systemic embolism), its components, and device-related thrombus between discharge and 45 days were evaluated. RESULTS: In 49,968 patients implanted with the Watchman FLX during the study period, the mean age was 77 years, and 40% were women. Postimplant DOAC/aspirin was prescribed in 24,497 patients, warfarin/aspirin in 3,913, and DAPT in 4,155. DAPT patients had more comorbid conditions than patients receiving OAC/aspirin. After propensity score matching, the 45-day composite endpoint rates were similar among the groups (DAPT = 3.44% vs DOAC/aspirin: 4.06%; P = 0.13 and DAPT = 3.23% vs warfarin/aspirin: 3.08%; P = 0.75). Death, stroke, and device-related thrombus were also similar; major bleeding was slightly increased in DOAC/aspirin patients (DAPT = 2.48% vs DOAC/aspirin = 3.25%; P = 0.04 and DAPT = 2.25% vs warfarin/aspirin = 2.22%; P = 0.93). CONCLUSIONS: In a large registry, DAPT had a similar safety profile compared with current Food and Drug Administration-approved postimplant drug regimens of OAC with aspirin following LAAO with the Watchman FLX. Shared decision making for nonpharmacologic stroke prevention should include a discussion of postprocedure medical therapy options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial AppendageStrokeAtrial FibrillationThrombosisHumansFemaleAgedMaleWarfarinPlatelet Aggregation InhibitorsAnticoagulantsTreatment OutcomeHemorrhageAspirinRegistries

Stichwörter der Autor:innen

anticoagulationantiplateletbleedingleft atrial appendage occlusionstroke

Substanzen

WarfarinPlatelet Aggregation InhibitorsAnticoagulantsAspirin

Autor:innen und Institutionen

  • University of Tennessee Health Science Center College of Medicine-Chattanooga and Erlanger Health System, Chattanooga, Tennessee, USA. Electronic address: Megan.Coylewright@erlanger.org.
  • Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Cardiac Electrophysiology Section, Division of Cardiology, Department of Medicine, University of California San Diego, San Diego, California, USA.
  • Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA.
  • Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA.

Förderung

  • NIA NIH HHS
  • Boston Scientific Corporation

Zitieren

APA

Coylewright, M., Holmes, D. R., Kapadia, S. R., Hsu, J. C., Gibson, D. N., Freeman, J. V., Yeh, R. W., Piccini, J. P., Price, M. J., Allocco, D. J., & Nair, D. G. (2023). DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX. JACC: Cardiovascular Interventions, 16(22), 2708-2718. https://doi.org/10.1016/j.jcin.2023.08.013

Vancouver

Coylewright M, Holmes DR, Kapadia SR, Hsu JC, Gibson DN, Freeman JV, et al. DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX. JACC: Cardiovascular Interventions. 2023;16(22):2708-2718. doi:10.1016/j.jcin.2023.08.013

BibTeX
@article{Coylewright2023,
  author = {Coylewright, Megan and Holmes, David R and Kapadia, Samir R and Hsu, Jonathan C and Gibson, Douglas N and Freeman, James V and Yeh, Robert W and Piccini, Jonathan P and Price, Matthew J and Allocco, Dominic J and Nair, Devi G},
  title = {DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  volume = {16},
  number = {22},
  pages = {2708--2718},
  doi = {10.1016/j.jcin.2023.08.013}
}
Kostenlos starten →